Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
G&E Herbal Biotechnology CoROCO:4911 +0.43%63 Interest Coverage is 5,898.20 as of Dec. 2025, which is 41% below its 10-year median of 10,000.00. GuruFocus rates ROCO:4911 with a GF Score™ of 63/100 and a GF Value™ of NT$86.94 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 376 Biotechnology companies, G&E Herbal Biotechnology Co ranks better than 63.03% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. G&E Herbal Biotechnology Co's
Operating Income
for the
three
months ended in Dec. 2025 was NT$29.5 Mil. G&E Herbal Biotechnology Co's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0.0 Mil.
G&E Herbal Biotechnology Co's interest coverage for the quarter that ended in Dec. 2025 was 5,898.20.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. G&E Herbal Biotechnology Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for G&E Herbal Biotechnology Co's Interest Coverage or its related term are showing as below:
ROCO:4911'
s Interest Coverage Range Over the Past 10 Years
Min: 2918.2 Med: No Debt Max: 20171
Current: 5251.76
ROCO:4911's Interest Coverage is ranked better than 63.03% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs ROCO:4911: 5251.76
G&E Herbal Biotechnology Co (ROCO:4911) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
G&E Herbal Biotechnology Co Interest Coverage Related Terms
G&E Herbal Biotechnology Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
G&E Herbal Biotechnology Co Interest Coverage Chart
ROCO:4911 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, G&E Herbal Biotechnology Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
G&E Herbal Biotechnology Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, G&E Herbal Biotechnology Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where G&E Herbal Biotechnology Co's Interest Coverage falls into.
G&E Herbal Biotechnology Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
G&E Herbal Biotechnology Co (ROCO:4911) has a Interest Coverage of 5,898.20 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on G&E Herbal Biotechnology Co and its competitors. This is 41% below median its historical median of 10,000.00. Over the past decade, G&E Herbal Biotechnology Co's Interest Coverage has ranged from 2,918.20 to 20,171.00. According to the industry distribution chart, G&E Herbal Biotechnology Co ranks #139 out of 376 companies in the Biotechnology industry, placing it in the top 37%.
Is G&E Herbal Biotechnology Co's Interest Coverage too high?
G&E Herbal Biotechnology Co's current Interest Coverage of 5,898.20 is 41% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 2,918.20 to a high of 20,171.00. The Biotechnology industry median Interest Coverage is 104.03. G&E Herbal Biotechnology Co's value of 5,898.20 is 5570% above this industry median. Based on the distribution chart, G&E Herbal Biotechnology Co ranks #139 out of 376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, G&E Herbal Biotechnology Co has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does G&E Herbal Biotechnology Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, G&E Herbal Biotechnology Co ranks #139 out of 376 companies for Interest Coverage. This puts G&E Herbal Biotechnology Co in the upper half of its industry. The industry median Interest Coverage is 104.03. G&E Herbal Biotechnology Co's value of 5,898.20 is 5570% above this benchmark. Historically, G&E Herbal Biotechnology Co's own Interest Coverage has ranged from 2,918.20 to 20,171.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 104.03, G&E Herbal Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. G&E Herbal Biotechnology Co's current Interest Coverage of 5,898.20 is 5570% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on G&E Herbal Biotechnology Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. G&E Herbal Biotechnology Co's current Interest Coverage is 5,898.20, which is 41% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is G&E Herbal Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, G&E Herbal Biotechnology Co (ROCO:4911) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.94, compared to a current price of NT$34.85 — trading 59.9% below its estimated fair value. The current Interest Coverage is 5,898.20, which is 41% below median its 10-year median of 10,000.00 and 5570% above the Biotechnology industry median of 104.03. G&E Herbal Biotechnology Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For G&E Herbal Biotechnology Co (ROCO:4911), the current Interest Coverage is 5,898.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is G&E Herbal Biotechnology Co (ROCO:4911) Overvalued in 2026?
Based on GuruFocus' analysis, G&E Herbal Biotechnology Co stock appears to be undervalued.
The current stock price of NT$34.85 is trading 59.9% below its estimated GF Value™ of NT$86.94.
GuruFocus considers G&E Herbal Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:4911:
Interest Coverage: 5,898.20 (41% below median its 10-year median of 10,000.00)
GF Value™: NT$86.94 vs. price of NT$34.85 (59.9% below fair value)
Industry Position: 5570% above the Biotechnology median (#139 of 376)
No single metric tells the full story. See the ROCO:4911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
G&E Herbal Biotechnology Co Ltd is a Taiwan-based biopharmaceutical company. It specializes in the production of Western conventional drugs, Chinese traditional drugs, unclassified food, cosmetics, and health products. The company is focused on botanical extraction technology and products. Its products include botanical extract toner, total moisture conditioning cream, whitening clear cream, and firming essence cream.
63GF Score
Get the complete analysis for ROCO:4911
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4911 has been successfully added to your 
